MARKET

GRTX

GRTX

Galera Therapeutics, Inc.
NASDAQ
0.1840
-0.0400
-17.86%
Pre Market: 0.1828 -0.0012 -0.65% 08:28 03/27 EDT
OPEN
0.2120
PREV CLOSE
0.2240
HIGH
0.2300
LOW
0.1760
VOLUME
35.01K
TURNOVER
0
52 WEEK HIGH
3.590
52 WEEK LOW
0.0853
MARKET CAP
10.01M
P/E (TTM)
-0.0970
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GRTX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at GRTX last week (0311-0315)?
Weekly Report · 03/18 09:34
Weekly Report: what happened at GRTX last week (0304-0308)?
Weekly Report · 03/11 09:33
Weekly Report: what happened at GRTX last week (0226-0301)?
Weekly Report · 03/04 09:34
Why TransMedics Group Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
TransMedics Group, Inc. Shares rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. The company's quarterly sales came in at $81.17 million. Janux Therapeutics and PubMatic were among the other stocks moving in pre- market trading.
Benzinga · 02/27 12:56
Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. The Dow Jones index closed lower by over 50 points on Monday. Dakota Gold Corp. And AmeriServ Financial are recent notable insider transactions for penny stocks. Galera Therapeutics, Inc. Is a biopharmaceutical company focused on cancer treatment.
Benzinga · 02/27 12:10
Weekly Report: what happened at GRTX last week (0219-0223)?
Weekly Report · 02/26 09:37
Weekly Report: what happened at GRTX last week (0212-0216)?
Weekly Report · 02/19 09:37
More
About GRTX
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a pipeline of therapeutic candidates to transform radiotherapy in cancer. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic in development for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) and for the reduction of esophagitis in patients with lung cancer. It has completed Phase III Reduction in Oral Mucositis with Avasopasem Manganese (ROMAN) trial of GC4419 for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. Its second dismutase mimetic product candidate, rucosopasem manganese (GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

Webull offers Galera Therapeutics Inc stock information, including NASDAQ: GRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRTX stock methods without spending real money on the virtual paper trading platform.